{"id":401977,"date":"2020-12-17T09:12:21","date_gmt":"2020-12-17T14:12:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401977"},"modified":"2020-12-17T09:12:21","modified_gmt":"2020-12-17T14:12:21","slug":"personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/","title":{"rendered":"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response <\/b><\/p>\n<p>MENLO PARK, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis\u2019 state-of-the-art tumor neoantigen prediction tool, SHERPA\u2122, with mechanisms of immune evasion to better predict response to cancer therapy.\n<\/p>\n<p>\nNEOPS combines the tumor genomic and immune-related analytics of the Personalis\u00ae NeXT Platform\u2122 to create a composite biomarker that can be more effective in predicting immunotherapy response than other, simpler biomarkers. NEOPS leverages Personalis\u2019 recently-launched machine learning-based tool, Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), which provides more accurate prediction of neoantigen presentation, a core mechanism in determining immunotherapy response.\n<\/p>\n<p>\nData presented at the AACR virtual meeting in June demonstrated that NEOPS significantly outperformed tumor mutational burden in predicting response to anti-PD-L1 therapy in a cohort of late-stage, unresectable melanoma patients, highlighting the potential of composite, neoantigen-based biomarkers to more effectively stratify responders and non-responders to immunotherapy. The prevalence of immune evasion events incorporated into NEOPS suggests that such composite neoantigen-based biomarkers are potentially applicable to a range of immunotherapies and cancer types.\n<\/p>\n<p>\n\u201cIdentifying effective biomarkers for cancer immunotherapy has proven challenging due to the complex biological mechanisms underlying patient response. We believe that more sophisticated, multimodal biomarker models like NEOPS represent the next step in this pursuit. By combining accurate tumor neoantigen prediction with mechanisms of immune evasion, we can create a more predictive model of therapy response,\u201d said Richard Chen, MD, Personalis CSO. \u201cNEOPS is the first of a new class of composite biomarkers for our pharma partners to utilize in their clinical trials. In the future, such biomarkers may be used to inform treatment decisions for patients.\u201d\n<\/p>\n<p>\nNEOPS, SHERPA, and other recent enhancements to the company\u2019s HLA typing and HLA LOH analytics represent the latest update to the comprehensive suite of advanced analytical engines of the Personalis NeXT Platform\u2122. Utilizing an augmented exome and transcriptome-based approach, NeXT enables the simultaneous analysis of both a tumor and its immune microenvironment from a single tumor specimen to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response.\n<\/p>\n<p><b>About Personalis, Inc.<\/b><\/p>\n<p>\nPersonalis, Inc. is a leader in cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient\u2019s cancer and immune response. The Personalis <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2Fimmunoid-next-platform%2F&amp;esheet=52350311&amp;newsitemid=20201217005356&amp;lan=en-US&amp;anchor=NeXT+Platform&amp;index=1&amp;md5=0a7dccdce994f7b3cd7ec08ec2d0226e\">NeXT Platform<\/a> is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2Fabout%2Flaboratory%2F&amp;esheet=52350311&amp;newsitemid=20201217005356&amp;lan=en-US&amp;anchor=Clinical+Laboratory&amp;index=2&amp;md5=4e0ae33623f341b536270049a009e9fc\">Clinical Laboratory<\/a> is GxP aligned as well as CLIA\u201988-certified and CAP-accredited. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2F&amp;esheet=52350311&amp;newsitemid=20201217005356&amp;lan=en-US&amp;anchor=www.personalis.com&amp;index=3&amp;md5=9ebf702d2a0f4b312b2e89a8e22d6027\">www.personalis.com<\/a> and follow Personalis on Twitter (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FPersonalisInc&amp;esheet=52350311&amp;newsitemid=20201217005356&amp;lan=en-US&amp;anchor=%40PersonalisInc&amp;index=4&amp;md5=9dbecb91637f9b67b8b7ab9e97159484\">@PersonalisInc<\/a>).\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements in this press release that are not historical are \u201cforward-looking statements\u201d within the meaning of U.S. securities laws, including statements relating to attributes or advantages of NEOPS, SHERPA or the Personalis NeXT Platform, the company\u2019s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis\u2019 filings with the U.S. Securities and Exchange Commission, including the company\u2019s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption \u201cRisk Factors.\u201d Personalis disclaims any obligation to update such forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201217005356\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201217005356\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Relations Contact for Personalis:<br \/>\n<br \/>Caroline Corner<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@personalis.com\">investors@personalis.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwestwicke.com%2F&amp;esheet=52350311&amp;newsitemid=20201217005356&amp;lan=en-US&amp;anchor=www.westwicke.com&amp;index=5&amp;md5=3d5330521a9c347e24ddb6e9dc0db8b5\">www.westwicke.com<br \/>\n<\/a><br \/>415-202-5678\n<\/p>\n<p>\nMedia Contact for Personalis:<br \/>\n<br \/>Jennifer Havlek<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:pr@personalis.com\">pr@personalis.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2F&amp;esheet=52350311&amp;newsitemid=20201217005356&amp;lan=en-US&amp;anchor=www.personalis.com&amp;index=6&amp;md5=5dd90897f60fe0c365593b4cb14c1b00\">www.personalis.com<br \/>\n<\/a><br \/>650-752-1300\n<\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Genetics Pharmaceutical Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201217005356\/en\/639161\/3\/Logo_Personalis_w-o_tag_correct.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis\u2019 state-of-the-art tumor neoantigen prediction tool, SHERPA\u2122, with mechanisms of immune evasion to better predict response to cancer therapy. NEOPS combines the tumor genomic and immune-related analytics of the Personalis\u00ae NeXT Platform\u2122 to create a composite biomarker that can be more effective in predicting immunotherapy response than other, simpler biomarkers. NEOPS leverages Personalis\u2019 recently-launched machine learning-based tool, Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), which provides more accurate prediction of neoantigen presentation, a core mechanism in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401977","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis\u2019 state-of-the-art tumor neoantigen prediction tool, SHERPA\u2122, with mechanisms of immune evasion to better predict response to cancer therapy. NEOPS combines the tumor genomic and immune-related analytics of the Personalis\u00ae NeXT Platform\u2122 to create a composite biomarker that can be more effective in predicting immunotherapy response than other, simpler biomarkers. NEOPS leverages Personalis\u2019 recently-launched machine learning-based tool, Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), which provides more accurate prediction of neoantigen presentation, a core mechanism in &hellip; Continue reading &quot;Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T14:12:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response\",\"datePublished\":\"2020-12-17T14:12:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/\"},\"wordCount\":693,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/\",\"name\":\"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-17T14:12:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/","og_locale":"en_US","og_type":"article","og_title":"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response - Market Newsdesk","og_description":"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis\u2019 state-of-the-art tumor neoantigen prediction tool, SHERPA\u2122, with mechanisms of immune evasion to better predict response to cancer therapy. NEOPS combines the tumor genomic and immune-related analytics of the Personalis\u00ae NeXT Platform\u2122 to create a composite biomarker that can be more effective in predicting immunotherapy response than other, simpler biomarkers. NEOPS leverages Personalis\u2019 recently-launched machine learning-based tool, Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), which provides more accurate prediction of neoantigen presentation, a core mechanism in &hellip; Continue reading \"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T14:12:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response","datePublished":"2020-12-17T14:12:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/"},"wordCount":693,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/","name":"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-17T14:12:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005356r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-announces-the-launch-of-neops-a-neoantigen-based-composite-biomarker-for-cancer-immunotherapy-response\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Personalis Announces the Launch of NEOPS\u2122, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401977"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401977\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}